In conclusion, we demonstrated that in vitro treatment with subtype-selective HDAC inhibitor chidamide alone or in combination with decitabine increased PRAME antigen-specific cytotoxicity of CTL through upregulation of PRAME and CD86 expression in AML cell lines. Here, HDAC9 is linked to acute myeloid leukemia.